Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Glycogen Synthase Kinase 3”

20 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 20 results

Testing effectiveness (Phase 2)Study completedNCT00948259
What this trial is testing

Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease

Who this might be right for
Alzheimer´s Disease
Noscira SA 30
Testing effectiveness (Phase 2)WithdrawnNCT03290963
What this trial is testing

Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine

Who this might be right for
Treatment Resistant Depression
William V. Bobo, M.D.
Not applicableStudy completedNCT02601859
What this trial is testing

Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment

Who this might be right for
Mild Cognitive Impairment
University of Dundee 11
Testing effectiveness (Phase 2)Study completedNCT04218071
What this trial is testing

Actuate 1901: 9-ING-41 in Myelofibrosis

Who this might be right for
Myelofibrosis
Actuate Therapeutics Inc. 17
Post-approval studies (Phase 4)Ended earlyNCT02686710
What this trial is testing

Comparison of the Effects of TIVA vs VIMA on Content of GSK-3beta in Leucocytes in On-pump Patients

Who this might be right for
Glycogen Synthase Kinase 3
Moscow Regional Research and Clinical Institute (MONIKI) 10
Post-approval studies (Phase 4)Study completedNCT00870311
What this trial is testing

Investigation of Lithium on Signal Transduction, Gene Expression and Brain Myo-Inositol Levels in Manic Patients

Who this might be right for
Bipolar Disorder
Wayne State University 28
Not applicableStudy completedNCT01049399
What this trial is testing

Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy

Who this might be right for
Progressive Supranuclear Palsy
Noscira SA 146
Testing effectiveness (Phase 2)WithdrawnNCT05116800
What this trial is testing

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Who this might be right for
Soft Tissue SarcomaUndifferentiated Pleomorphic SarcomaMyxofibrosarcoma+10 more
Brown University
Not applicableStudy completedNCT05687474
What this trial is testing

Baby Detect : Genomic Newborn Screening

Who this might be right for
Congenital Adrenal HyperplasiaFamilial Hyperinsulinemic Hypoglycemia 1Phosphoglucomutase 1 Deficiency+121 more
Centre Hospitalier Universitaire de Liege 6,824
Testing effectiveness (Phase 2)WithdrawnNCT04832438
What this trial is testing

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Who this might be right for
Salivary Gland CarcinomaAdenoid Cystic CarcinomaSalivary Gland Cancer+1 more
Actuate Therapeutics Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT03678883
What this trial is testing

9-ING-41 in Patients With Advanced Cancers

Who this might be right for
CancerPancreatic CancerSarcoma+22 more
Actuate Therapeutics Inc. 350
Testing effectiveness (Phase 2)Ended earlyNCT05239182
What this trial is testing

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

Who this might be right for
Pancreatic Adenocarcinoma
Anwaar Saeed 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT05077800
What this trial is testing

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Who this might be right for
Pancreatic AdenocarcinomaPancreatic Adenocarcinoma Metastatic
Colin D. Weekes, M.D., PhD 70
Testing effectiveness (Phase 2)Looking for participantsNCT06174220
What this trial is testing

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Who this might be right for
Arrhythmogenic CardiomyopathyArrhythmogenic Right Ventricular Cardiomyopathy
Hamilton Health Sciences Corporation 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT05010629
What this trial is testing

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Who this might be right for
Salivary Gland CancerRecurrent Salivary Gland CancerMetastatic Cancer+1 more
Glenn J. Hanna 35
Testing effectiveness (Phase 2)Study completedNCT00088387
What this trial is testing

Effect of Lithium and Divalproex in Alzheimer's Disease

Who this might be right for
Alzheimer Disease
National Institute of Neurological Disorders and Stroke (NINDS) 35
Early research (Phase 1)Looking for participantsNCT06896188
What this trial is testing

9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

Who this might be right for
Pancreatic Adenocarcinoma
Anwaar Saeed 12
Testing effectiveness (Phase 2)WithdrawnNCT04906876
What this trial is testing

9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Who this might be right for
SarcomaSoft Tissue SarcomaMetastatic Sarcoma+10 more
Brown University
Not applicableUnknownNCT02635269
What this trial is testing

Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy

Who this might be right for
Metabolism, Inborn ErrorsLipid Metabolism, Inborn ErrorsCarbohydrate Metabolism, Inborn Errors+20 more
Rigshospitalet, Denmark 60
Early research (Phase 1)Ended earlyNCT04239092
What this trial is testing

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Who this might be right for
Refractory CancerRefractory NeoplasmCancer Pediatric+8 more
Actuate Therapeutics Inc. 40